🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSurvodutide MASH Phase 2b — need advice Page 3

Survodutide MASH Phase 2b — need advice

FranDenver Thu, Mar 7, 2024 at 10:16 PM 16 replies 2,044 viewsPage 3 of 4
hannah_MT
New Member
23
89
Feb 2026
Bozeman, MT
Mar 14, 2024 at 6:14 PM#11
Dr.EM_Chicago said:
The liver data is among the strongest non-weight findings in the class.

This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.

4 2nick_newbie, DadBodDave, AmyNC_wife and 1 other
Reply Quote Save Share Report
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Mar 17, 2024 at 6:28 AM#12

Clinical perspective, offered as context rather than as advice. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

5 3Dr.NateNeph, PharmD_Rodriguez, julia.endo and 2 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Mar 19, 2024 at 6:41 PM#13
Dr.Martinez said:
It is worth asking what the claim would look like if it were false.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

6 4MikeNYC_runner and 3 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Mar 22, 2024 at 6:52 AM#14

Adding the numbers, since they settle part of this. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

That is the short version; the long version is somebody else's post.

7 5KarenAZ_mom, zoe_NC, Dr.ObesityLA and 4 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Mar 24, 2024 at 7:02 PM#15

Moderator note: a couple of off-topic posts removed. Report rather than reply if it drifts again.

8 6PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 5 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register